Lyophilized (freeze-dried) GLP-1 preparations offer stability advantages over liquid formulations, but they require a reconstitution step before administration. Done correctly, reconstitution produces a potent, sterile preparation ready for patient use. Done incorrectly, it can introduce contamination, alter the concentration, or damage the active ingredient.

This guide walks through the reconstitution process step by step, covering diluent selection, aseptic technique, visual inspection, labeling, and storage after reconstitution.

Before reconstituting a lyophilized GLP-1 preparation, gather the following:

• The lyophilized vial (within its pre-reconstitution BUD)
• The correct diluent in the correct volume (per the pharmacy's instructions)
• A sterile syringe and needle appropriate for the diluent volume
• Alcohol swabs (70% isopropyl alcohol)
• A clean, flat work surface (ideally in a designated clean area)
• A label for the reconstituted vial (to record reconstitution date and post-reconstitution BUD)
• Gloves

Before touching the diluent, inspect the lyophilized vial:

• Check the BUD: Confirm the pre-reconstitution BUD has not passed. If it has, discard the vial — do not reconstitute.
• Inspect the vial: Look for cracks, chips, or damage to the vial or stopper. Discard any damaged vials.
• Inspect the powder: The lyophilized cake or powder should appear uniform and dry. Discoloration, clumping, or visible moisture may indicate a compromised preparation.
• Check the seal: The aluminum crimp seal should be intact. If the seal is damaged or the stopper appears to have been punctured, discard the vial.
• Verify storage conditions: Confirm the vial has been stored as labeled. If there is any reason to believe the vial experienced a temperature excursion or moisture exposure, contact the pharmacy before proceeding.

The diluent used for reconstitution matters. Using the wrong diluent can affect the stability, pH, and compatibility of the preparation. Always follow the pharmacy's specific instructions for diluent selection.

Common diluents for lyophilized GLP-1 preparations include:

Bacteriostatic Water for Injection (BWFI):

• Contains 0.9% benzyl alcohol as a preservative
• Extends the post-reconstitution BUD by inhibiting microbial growth
• Appropriate for multi-dose vials where the preparation will be used over several days or weeks
• Not appropriate for patients with benzyl alcohol sensitivity or for neonates

Sterile Water for Injection (SWFI):

• Contains no preservative
• Results in a shorter post-reconstitution BUD (typically 24 hours or less for unpreserved preparations)
• Appropriate for single-dose use or when benzyl alcohol is contraindicated

Sterile Normal Saline (0.9% NaCl):

• May be used for some preparations — follow pharmacy instructions
• Check compatibility with the specific preparation

If the pharmacy's instructions do not specify a diluent, contact the pharmacy before proceeding. Do not substitute diluents without confirmation.

The volume of diluent added determines the final concentration of the reconstituted preparation. The pharmacy's label or package insert will specify the volume to add to achieve the labeled concentration.

For example, if a vial contains 5 mg of lyophilized semaglutide and the instructions specify adding 2 mL of BWFI, the resulting concentration will be 2.5 mg/mL.

Do not estimate the volume. Use a calibrated syringe and measure precisely. An incorrect volume will result in an incorrect concentration, which can lead to dosing errors.

Aseptic technique is critical when reconstituting sterile preparations. The goal is to prevent introducing microorganisms into the vial during the reconstitution process.

Hand hygiene: Wash hands thoroughly with soap and water, then don clean gloves.

Clean the work surface: Wipe the work surface with a 70% isopropyl alcohol swab and allow it to dry.

Swab the stoppers: Wipe the stopper of the lyophilized vial and the stopper of the diluent vial with separate 70% isopropyl alcohol swabs. Allow to dry for at least 30 seconds before puncturing.

Draw the diluent: Using a sterile syringe and needle, draw the correct volume of diluent from the diluent vial.

Add the diluent to the lyophilized vial: Insert the needle through the center of the stopper of the lyophilized vial. Direct the stream of diluent against the inside wall of the vial rather than directly onto the powder cake — this minimizes foaming and mechanical disruption of the powder.

Do not shake. Shaking can cause foaming and aggregation of the peptide. Instead, gently swirl the vial in a circular motion until the powder is completely dissolved.

Allow time for complete dissolution. Some lyophilized preparations dissolve quickly; others may take several minutes. Do not proceed until the powder is completely dissolved and the solution is clear.

After the powder has dissolved, inspect the reconstituted solution carefully:

• Clarity: The solution should be clear. Cloudiness or turbidity may indicate incomplete dissolution, aggregation, or contamination.
• Color: The solution should match the expected color described in the pharmacy's instructions (typically colorless to slightly yellow for GLP-1 preparations).
• Particulates: Hold the vial up to a light source and look for visible particles. Any visible particles are grounds for discarding the preparation.
• Foam: Some foaming during reconstitution is normal, but the foam should dissipate before use. Persistent foam may indicate a problem.

If the reconstituted solution does not pass visual inspection, do not use it. Contact the pharmacy.

This step is critical for compliance and patient safety. Immediately after reconstitution, label the vial with:

• Reconstitution date and time
• Post-reconstitution BUD (per the pharmacy's instructions — typically 14–28 days refrigerated if BWFI was used)
• Your initials (or the initials of the person who performed the reconstitution)
• Storage conditions (refrigerate at 2–8°C)

The post-reconstitution BUD is different from the pre-reconstitution BUD printed on the original label. Once reconstituted, the preparation must be used within the post-reconstitution BUD, regardless of the original label date.

Store the reconstituted vial refrigerated at 2–8°C immediately after reconstitution. Do not freeze. Protect from light if labeled as light-sensitive.

Log the reconstituted vial in your clinic's medication inventory, including the reconstitution date and post-reconstitution BUD.

• Using the wrong diluent or volume: Always follow pharmacy instructions precisely
• Shaking the vial: Swirl gently — shaking causes aggregation
• Skipping visual inspection: Never administer a preparation that does not pass visual inspection
• Forgetting to label with post-reconstitution BUD: This is a compliance requirement
• Storing at room temperature after reconstitution: Reconstituted preparations must be refrigerated
• Using a preparation past its post-reconstitution BUD: Discard and reconstitute a new vial

1. United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. 2023 Revision.
2. U.S. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. FDA, 2004.
3. Institute for Safe Medication Practices. ISMP Guidelines for Safe Preparation of Compounded Sterile Preparations. ISMP, 2016.
4. Trissel LA. Handbook on Injectable Drugs. 18th ed. American Society of Health-System Pharmacists, 2014.
5. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. AJHP, 2014.

MedClinic Partners connects licensed clinics and 503A pharmacies with vetted 503B supply and USA-made cGMP RUO peptides. Questions about clinical procedures or supply? Use the Get Connected form to reach our team.